{"id":"W2890529757","doi":"10.1200/jco.2017.35.15_suppl.5587","title":"Exploratory phase II evaluation of cabozantinib in recurrent/metastatic uterine carcinosarcoma (CS): A study of the Princess Margaret, Chicago, and California phase II consortia.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre","funders":"","keywords":"Medicine; Cabozantinib; Internal medicine; Progression-free survival; Oncology; Cohort; Cancer; Endometrial cancer; Carcinosarcoma; Everolimus; Phases of clinical research; Chemotherapy; Gastroenterology; Urology; Carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003993152,0.001212439,0.00109,0.0004802697,0.0005161721,0.0007950898,0.0008802015,0.001281049,0.004639703],"category_scores_gemma":[0.001731467,0.0006338699,0.001358696,0.0005316171,0.0007607591,0.000618798,0.0004514703,0.001933845,0.0008216614],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001340751,"about_ca_system_score_gemma":0.003666317,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002897441,"about_ca_topic_score_gemma":0.01160375,"domain_scores_codex":[0.9993357,0.0003663367,0.00003072722,0.0001089709,0.00007293744,0.00008535412],"domain_scores_gemma":[0.9984713,0.0002153701,0.0002809416,0.0001200129,0.0001485452,0.0007637732],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7131038,0.06296851,0.02455398,0.001654813,0.003664203,0.0004998315,0.0007960653,0.003172401,0.03978051,0.0006614165,0.01938407,0.1297604],"study_design_scores_gemma":[0.6584648,0.2905407,0.03340631,0.0001406058,0.001511984,0.0005306525,0.0001539192,0.00113091,0.002571223,0.0002419709,0.01126566,0.00004127462],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9683477,0.006838717,0.001182315,0.00100576,0.000166839,0.01307323,0.005055038,0.0001697782,0.004160698],"genre_scores_gemma":[0.9604995,0.005417323,0.005001399,0.002186442,0.0002184666,0.01262492,0.008946241,0.00006236977,0.005043332],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004639703,"threshold_uncertainty_score":0.02111804,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2760814337365475,"score_gpt":0.539506538901688,"score_spread":0.2634251051651405,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}